Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 1;13(6):1062-1064.
doi: 10.21037/hbsn-24-607. Epub 2024 Nov 21.

Surrogate endpoints in clinical trials: when is good...good enough?

Jamie Olapo Schnuck  1   2 , Sardar Shahmir B Chauhan  1   2 , Jonathan G Sham  1   2
Affiliations
Editorial

Surrogate endpoints in clinical trials: when is good...good enough?

Jamie Olapo Schnuck et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Overall survival (OS); clinical trials; hepato-biliary-pancreatic malignancies; recurrence-free survival (RFS); surrogate endpoints.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-24-607/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun 2018;11:156-64. 10.1016/j.conctc.2018.08.001 - DOI - PMC - PubMed
    1. Fiteni F, Westeel V, Pivot X, et al. Endpoints in cancer clinical trials. J Visc Surg 2014;151:17-22. 10.1016/j.jviscsurg.2013.10.001 - DOI - PubMed
    1. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-70. 10.1200/JCO.2005.01.6071 - DOI - PubMed
    1. Oba K, Paoletti X, Alberts S, et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst 2013;105:1600-7. 10.1093/jnci/djt270 - DOI - PMC - PubMed
    1. Harshman LC, Xie W, Moreira RB, et al. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. Cancer 2018;124:925-33. 10.1002/cncr.31154 - DOI - PubMed

LinkOut - more resources